Leukemias | Clinical

Blinatumomab Improves Survival Outcomes Over Chemotherapy in High-Risk B-ALL

March 03, 2021

Blinatumomab consolidation demonstrated significantly prolonged event-free survival in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia when compared with chemotherapy before allogeneic hematopoietic stem cell transplantation.

Sabatolimab Demonstrates Promising Efficacy in Acute Myeloid Leukemia, Myelodysplastic Syndrome

January 02, 2021

In a phase 1b clinical trial presented during the 2020 American Society of Hematology Annual Meeting, investigators sought to determine the efficacy and safety of the novel TIM-3–targeting IgG4 antibody sabatolimab in combination with hypomethylating agents as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.